Category: New Investments

April 23, 2024

Charting A New Course For Chronic Cough Treatment

Chronic cough, particularly when it extends beyond 8 weeks into what is known as refractory chronic cough (RCC), represents a substantial health challenge. With its prevalence globally ranging from 2% to 18%, RCC places a significant burden on individuals and healthcare systems due to its profound physical and psychological impact on patients....Read the Full Article

April 22, 2024

Building a Potential Cure for Type 1 Diabetes

Over 300K Canadians, +1.5M Americans, and +9M individuals globally are living with Type 1 Diabetes. Although a seemingly difficult-to-treat disease, over the last several years there has been a strong wave of innovation and renewed interest in the space from big pharma and investors alike. For Lumira, we see the Type 1...Read the Full Article

February 22, 2024

Advancing Next-Gen Gene Editing to Combat Genetic Diseases

Gene editing holds incredible potential to cure a wide range of genetic diseases by directly altering DNA in the genome inside cells. Yet, today's gene editors remain facing many limitations. "Current gene editing technologies are constrained by low on-target editing efficiency and high unintended off-target effects," noted Dr. Daniel Hetu, Managing Director...Read the Full Article

February 22, 2024

Bridging The Gap: A Platform to Address Cognitive Deficits

Cognitive deficits are the hallmark of a variety of psychiatric and neurodegenerative disorders affecting millions of patients worldwide.   These conditions include; major depressive disorder (MDD), schizophrenia, a number of neurodegenerative disorders including Alzheimer’s Disease, and aging in general.  Treatment options are few and far between and in many cases no treatment options...Read the Full Article

Scroll to Top